Ignite Creation Date:
2025-12-25 @ 2:03 AM
Ignite Modification Date:
2025-12-31 @ 11:06 AM
Study NCT ID:
NCT07087860
Status:
RECRUITING
Last Update Posted:
2025-12-09
First Post:
2025-07-16
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers
Sponsor:
Mayo Clinic
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-08-01
Start Date Type:
ACTUAL
Primary Completion Date:
2028-08-07
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-08-07
Completion Date Type:
ESTIMATED
First Submit Date:
2025-07-16
First Submit QC Date:
None
Study First Post Date:
2025-07-28
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-02
Last Update Post Date:
2025-12-09
Last Update Post Date Type:
ESTIMATED